{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016645","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.164805+00:00","generated_at":"2026-06-22T05:04:48.134819+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a","bullets":["Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.","Cash $654.6M; funding through 2025; year-end 2022 cash guided at $575-600M.","XmAb564 Phase 1a: single-dose well-tolerated; 117-fold peak CD25 bright Treg expansion; Phase 1b in atopic dermatitis/psoriasis started.","Vudalimab Phase 2 in mCRPC; plamotamab Phase 2 enrolling; data at SITC and ASH.","Vir royalty $17.8M in Q3; Zenas raised $118M, plans Phase 3 for obexelimab."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016645","json":"https://secwatch.observer/filing/0001558370-22-016645.json","markdown":"https://secwatch.observer/filing/0001558370-22-016645.md","text":"https://secwatch.observer/filing/0001558370-22-016645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/0001558370-22-016645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/xncr-20221107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:04:48.134819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b19f7ebda0050fc0e92c8ab340aa9b8be4ab3b53","claim":"Xencor Inc reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 7, 2022, Xencor, Inc. announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022016645/0001558370-22-016645-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}